Lexicon Pharmaceuticals | LXRX - Cash And Equivalent


Lexicon Pharmaceuticals reported $38.09M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Illumina USD 1.42B 368M Dec/2025
Insmed USD 582.19M 71.74M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
MannKind USD 52.83M 22.05M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025